Biological markers in lung cancer: A clinician's perspective

Cancer Biomarkers

Volumn 6, Issue 3-4, 2009, Pages 123-135

  Tufman, Amanda ^a   Huber, Rudolph Maria ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

bevacizumab; biomarker; chemotherapy; cisplatin; diagnosis; EGFR; erlotinib; gefitinib; gemcitabine; genomics; histology; IGFR; immunehistochemistry; Lung cancer; non small cell lung cancer; pemetrexed; proteomics; screening; small cell lung cancer; sputum cytology; staging; targeted therapy; treatment; tumor marker; VEGF

Indexed keywords

BETA THROMBOGLOBULIN; BETA TUBULIN; BEVACIZUMAB; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CHROMOGRANIN A; CISPLATIN; CYTOKERATIN 19 FRAGMENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; NAVELBINE; NEURON SPECIFIC ENOLASE; PACLITAXEL; PEMETREXED; PROGASTRIN RELEASING PEPTIDE; TEMSIROLIMUS; VASCULOTROPIN; TUMOR MARKER;

ADVANCED CANCER; ANGIOGENESIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG BINDING; ENZYME BLOOD LEVEL; FATIGUE; HAIR LOSS; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY METASTASIS; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SPUTUM CYTODIAGNOSIS; THORAX RADIOGRAPHY; VOMITING; CHEMISTRY; GENETICS; LUNG NEOPLASMS; PROCEDURES;

HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 77958175711     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2009-0124     Document Type: Review

References (97)

1. W. A. Alberts, Diagnosis and Management of Lung Cancer Executive Summary: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition), Chest 132 (Suppl 3) (2007).
2. M. Al-Haddad and M. B. Wallace, Molecular diagnostics of non-small cell lung cancer using mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration, Cytopathology 17 (2006), 3-9.
3. F. Andre, D. Grunenwald, J. Pignon et al., Survival of Patients with Resected N2 Non-Small-Cell Lung Cancer: Evidence for a Subclassification and Implications, Journal of Clinical Oncology 18 (16) (2000).
4. P. Anglim, T. Alonzo and I. Laird-Offringa, DNA methylationbased biomarkers for early detection of non-small cell lung cancer: an update, Molecular Cancer 7 (81) (2008).
5. O. Arrieta, D. Saavedra-Perez and R. Kuri, Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis, 9 (119) BMC Cancer (2009).
6. P. Bach, D. Niewoehner and W. Black, Screening for Lung Cancer: The Guidelines 2003, Chest 123 (Suppl 1) (2003).
7. H. Bai, L. Mao, H. Wang et al., Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer, Journal of Clinical Oncology 27 (2009).
8. J. F. Battey, P. H. Braun, E. R. Gritz et al., Primary and seconadry prevention of lung cancer: an IASLC workshop, Lung Cancer 12 (19) (1995).
9. M. B. Beasley, Immunohistochemistry of Pulmonary and Plerual Neoplasia, Arch Pathol Lab Med 132 (2008).
10. J. Behr, A. Buck, S. Gallenberger et al., Diagnostik des Lungenkarzinoms, in: Tumor Manual: Tumoren der Lunge und des Mediastinums: Empfehlungen zur Diagnostik, Therapie und Nachsorge, R. Huber, ed., Tumorzentrum, Munich and W. Zuckschwerdt Verlag, Munich, 2009, pp. 11-40.
11. D. Bell, T. Lynch, S. Haserlat et al., Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non-Small-Cell Lung Cancer: Molecular Analysis of the IDE-AL/INTACT Gefitinib Trials, J Clin Oncol 23 (31) (2005).
12. G. Bepler, I. Kusmartseva and S. Sharma, RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non-Small-Cell Lung Cancer, J Clin Oncol 24 (2006), 4731-4737.
13. E. Cabebe and H. Wakelee, Role of Anti-angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors, Current Treatment Opinions in Oncology 8 (2007), 15-27.
14. F. Cappuzzo, L. Toschi and G. Tallini, Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer serviva in non-small-cell lung cancer patients treated with gefitinib, Annals of Oncology 17 (7) (2006).
15. G. Carpagnano, M. Foschino-Barbaro, A. Spavevello et al., 3p Microsatellite Signature in Exhaled Breath Condenstae and Tumor Tissue of Patients with Lung Cancer, Am J Respir Crit Care Med 177 (2008) 337-341.
16. D. Conrad, J. Goyette and P. Thomas, Proteomics as a Method for Early Detection of Cancer: A Review of Proteomics, Exhaled Breath Condenstae and Lung Cancer Screening, JGIM 23 (2007) (Suppl 1), 78-84.
17. T. D'Amico, Molecular Biologic Staging of Lung Cancer, Ann Thorac Surg 85 (2008), 737-742.
18. R. Danesi, G. Altavilla, E. Giovannetti and R. Rosell, Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors, Pharmacogenomics 10 (1) (2009), 69-80.
19. W. De Roock, J. De Schutter, G. De Hertogh et al., KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab, JCO 25 (18) (2007) ASCO Annual Meeting Proceedings Part I. S 4132.
20. L. Ding, G. Getz, D. Wheeler et al., Somatic mutations affect key pathways in lung adenocarcinoma, Nature 455 (23) (2008).
21. C. Dooms, E. Verbeken, S. Stroobants et al., Prognostic Stratification of Stage IIIA-N2 Non-Small-Cell Lung Cancer After Induction Chemotherapy: AModel Based on the Combination of Morphometric-Pathologic Response in Mediastinal Nodes and Primary Tumor Response on Serial 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography, J Clin Oncol 26 (7) (2008).
22. J. Engelman, K. Zejnullahu, Mitsudomi et al., MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling, Science 316 (2007).
23. T. Esscher, L. Steinholtz, J. Bergh et al., Neurone specific enolase: a useful diagnostic serum marker for small cell carcinoma of the lung, Thorax 40 (1985), 85-90.
24. Y. Fan, P. Hu, Y. Jiang et al., Association between Sputum Atypia and Lung Cancer Risk in an Occupational Cohort in Yunnan, China, Chest 135, (2009) 778-785.
25. N. Ferrara, H. Gerber and J. LeCouter, The Biology of VEGF and its receptors, Nature Medicine 9 (6) (2003).
26. V. Gregorc, V. Ludovini, L. Pistola et al., Relevance of p53, bcl-2 and Rb expression on resi stance to cisplatin-based chemotherapy in advanced non-small cell lung cancer, Lung Cancer 39 (2003) 41-48.
27. C. Gridelli, P. Maione and A. Rossi, The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer, The Oncologist 13 (2008), 139-147. (Pubitemid 351342577)
28. P. Gu, G. Huang and Y. Chen, Diagnostic Utility of Pleural Fluid Carcinoembryonic Antigen and CYFRA 21-1 In Patients With Pleural Effusion: A Systematic Review and Meta-Analysis, Journal of Clinical Laboratory Analysis 21 (2007), 398-405.
29. H. Haimoto, Y. Takahashi, T. Koshikawa et al., Immunohistochemical localization of gamma-enolase in normal human tissues other than nervous and neuroendocrine tissues, Lab Invest 52 (3) (1985), 257-263.
30. R. Herbst, J. Heymach and S. Lippman, Molecular Origins of Cancer: Lung Cancer, N Engl J Med 359 (13) (2008).
31. S. Holdenrieder, P. Stieber, H. Bodenmüller et al., Circulating Nucleosomes in Serum, Annals New York Academy of Sciences 945 (2006), 93-102.
32. S. Holdenrieder, P. Stieber, J. von Pawel et al., Circulating Nucleosomes Predict the Response to Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer, Clinical Cancer Research 10 (2004), 5981-5987.
33. S. Holdenrieder, J. von Pawl, E. Dankelmann et al., Nucleosomes, ProGRP, NSE, CYFRA 21-1 and CEA in Monitoring First-Line Chemotherapy of Small Cell Lung Cancer, Clin Cancer Res 14 (3) (2008).
34. S. Holdenrieder, J. von Pawel, E. Dankelmann et al., Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer, Lung Cancer 63 (2009), 128-135.
35. G. Hwang, M. Ahn, B. Park et al., ERCC1 Expression as a Prognostic Marker in N2 (+) Nonsmall-Cell Lung Cancer Patients Treated With Platinum-based Neoadjuvant Concurrent Chemoradiotherapy, Cancer 113 (6) (2008).
36. J. Jakupciak, S. Maragh, M. Markowitz, A. Greenberg et al., Performance of mitochondrial DNA mutations detecting early stage cancer, BMC Cancer 8 (285) (2008).
37. K. Kagohashi, H. Satoh, H. Ishikawa et al., A re-evalutation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer, Med Oncol 25 (2008), 187-189.
38. K. Kalikaki, Koutsopoulos et al., Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC, British Journal of Cancer 99 (2008), 923-929.
39. F. Kamangar, G. Dores and W. Anderson, Patterns of Cancer Incidence, Mortality and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World, J Clin Oncol 24 (4) (2006).
40. J. Katzel, M. Fanucchi and L. Zujun, Recent advances of novel targeted therapy in non-small cell lung cancer, Journal of Hematology and Oncology 2 (2) (2009).
41. S. Kim, J. Jeong, M. Kin, H. Cho et al., Efficacy of Gemcitabine in Patients with Non-Small Cell Lung Cancer According to Promoter Polymorphisms of the Ribonucleotide Reductase M1 Gene, Clin Cancer Res 14 (10) (2008).
42. T. King, W. Akerley and A. Fan, p53 Mutations do not predict response to paclitatxel in metastatic nonsmall cell lung carcinoma, Cancer 89 (2000), 769-773.
43. S. Kobayashi, T. Boggon, T. Dayaram et al., EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib, NEJM 352 (8) (2005).
44. S. La Monica, M. Galetti, R. Alfieri et al., Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines, Biochemical Pharmacology (2009) doi:10.1016/j.bcp. 2009.04.033.
45. H. Linardou, I. Dahabreh, D. Kanaloupiti et al., Assessment of somatic k-RAS mutations as a mechanism associated with resi stance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer, The Lancet 9 (2008).
46. R. Lord, J. Brabender, D. Gandara et al., Low ERCC1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer, Clin Cancer Res 8 (2002), 2286-2291.
47. V. Ludovini, G. Bellezza, L. Pistola et al., High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected nonsmall-cell lung cancer patients, Annals of Oncology (2009) doi:10.1093/annonc/mdn727.
48. T. Lynch, D. Bell, R. Sordella et al., Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib, NEJM 3502 (1) (2004).
49. S. Maheswaran, L. Sequist, S. Nagrath et al., Detection of Mutations in EGFR in Circulating Lung-Cancer Cells, NEJM 359 (4) (2008).
50. Marchi, Cavaglia et al., Peripheral markers of blood-brain barrier damage, Clinica Chimica Acta 342 (2004), 1-12.
51. Marchi, Mazzone et al., ProApolipoprotein A1: A Serum Marker of Brain Metastases in Lung Cancer Patients, Cancer 112 (6) (2008).
52. R. Menezes, H. Roberts, N. Paul et al., Lung cancer screening using low-dose computed tomography in at-risk individuals: The Toronto experience, Lung Cancer (2009), DOI:10.1016/j.lungcan. 2009.03.030.
53. T. Mineo, A. Vincenzo, E. Pompeo and A. Baldi, Immunohitochemistry- detected microscopic tumor spread affects outcome in en-bloc resection for T3-chest wall lung cancer, European Journal of Cardio-thoracic Surgery 31 (2007), 1120-1124.
54. R. Molina, J. Auge, J. Escudero et al., Mucins CA125, Ca19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Canacer: Comparison with CYFRA 21-1, CEA, SCC and NSE, Tumor Biol 29 (2008), 371-380.
55. R. Molina, J. M. Auge, X. Filella et al., Pro-gastrin-releasing prptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC CYFRA 21-1 and NSE in patients with lung cancer, Anticancer Research 25 (3 A) (2005), 1773-1778.
56. J. Molina, P. Yang, S. Cassivi et al., Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship, Mayo Clin Proc 83 (5) (2008), 584-594.
57. F. Morgillo, W. Kim, E. Kin et al., Implication of the Insulinlike Growth Factor-IR Pathway in the Resistance of Nonsmall Cell Lung Cancer Cells to Treatment with Gefitinib, Clin Cancer Res 13 (9) (2007).
58. K. O'Byrne, I. Bondarenko, C. Barrios et al., Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study, J Clin Oncol 27 (15 s) (2009), (suppl; abstr 8007).
59. Y. Ohe, Y. Ichinose, Y. Nishiwaki et al., Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients with advanced non-small-cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan, J Clin Oncol 27 (15 s) (2009), (suppl. Abstr. 8044).
60. K. Olaussen, A. Dunant and P. Fouret, DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-based Adjuvant Chemotherapy, NEJM 355 (10) (2006).
61. S. Oudard, J. Medioni, J. Ayllon et al., Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma, Expert Rev Anticancer Ther 9 (6) (2009), 705-717.
62. J. Paez, P. Jänne and J. Lee, EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy, Science 304 (2004).
63. K. Pandya, S. Dahlberg, M. Hidalgo et al., A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500), Journal of Thoracic Oncology 2 (11) (2007).
64. W. Pao, V. Miller, M. Zakowski et al, EGF Receptor gene mutations are common in lung cancers from, never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib, PNAS 101 (36) (2004).
65. V. Papadimitrakopoulou, J. Soria, J. Douillard et al., A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I), J Clin Oncol 25 (18 S) (2007) June 20 Suppl. 7589.
66. D. Parkin, F. Bray, J. Ferlay, and P. Pisani, Global Cancer Statistics 2002, CA Cancer J Clin 55 (2005) 74-108.
67. R. Pirker, J. Pereira, A. Szczesna et al., Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, Lancet 373 (2009) 1525-1531.
68. Reck, Martin, Gefitinib in the treatment of advanced nonsmall-cell lung cancer, Expert Rev Anticancer Ther 9 (4) (2009), 401-412.
69. M. Reed, M. Molloy, E. Dalton and J. Howington, Survival after resection for lung cancer is the outcome that matters, Am J Surg (2004).
70. J. Riedemann and V. Macaulay, IGF1R signalling and its inhibition, Endocrine-Related Cancer 13 (2006), S33-S43.
71. G. Riely, J. Marks and W. Pao, KRAS Mutations in Non-Small Cell Lung Cancer, Proc Am Thorac Soc 6 (2009), 201-205.
72. R. Rosell, K. Danenberg and V. Alberola, Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients, Clinical Cancer Research 10 (2004), 1318-1325. (Pubitemid 38365223)
73. L. Rubio, F. J. Vera-Sempere, J. A. Lopez-Guerrero et al., A risk model for non-small cell lung cancer using clinicopathological variables, angiogenesis and oncoprotein expression, Anticancer Res 1 B (2005), 497-504.
74. D. Rüttinger, N. van den Engel, H. Winter et al., Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response, Journal of Translational Medicine 5 (43) (2007).
75. A. Sandler, R. Gray, M. Perry et al., Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer, N Engl J Med 355 (24) (2006).
76. G. Scagliotti, N. Hanna, F. Fossella et al., The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies, The Oncologist 14 (2009), 253-263.
77. G. Scagliotti, P. Parikh, J. von Pawel et al., Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients with Advanced-Stage Non-Small-Cell Lung Cancer, J Clin Oncol 26 (2008), 3543-3551.
78. J. Schiller, D. Harrington, C. Belani et al., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med 246 (2) (2002).
79. P. Seve, J. Mackey, S. Isaac et al., Class III Beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancerreceiving paclitaxel, Mol Cancer Ther 4 (12) (2005).
80. F. Shepherd and R. Rosell, Weighing Tumor Biology in Treatment Decisions for Patients with Non-Small Cell Lung Cancer, JTO 2 (6) (2007), Suppl 2.
81. S. Sone, T. Nakayama, T. Honda et al., Long-term follow-up study of a population-based 1996-1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography, Lung Cancer 58 (2007), 329-341.
82. M. Sos, M. Koker, B. Weir et al., PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR, Cancer Res 69 (8) (2009).
83. S. Sridhar and P. Goodwin, Insulin-Insulin-Like Growth Factor Axis and Colon Cancer, J Clin Oncol 27 (2) (2009).
84. P. Stieber, S. Holdenrieder and R. Lamerz, Immunologische Diagnostik und Tumormarker, in Tumor Manual: Tumoren der Lunge und des Mediastinums: Empfehlungen zur Diagnostik, Therapie und Nachsorge, R. Huber, ed., Tumorzentrum, Munich and W. Zuckschwerdt Verlag, Munich, 2009, pp. 41-52.
85. P. Therasse, S. B. Arbuck, E. A. Eisenhauer et al., New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst 92 (2000), 205-216.
86. U. S. Preventive Services Task Force, Lung Cancer Screening: Recommendation Statement, Ann Intern Med 140 (2004), 738-739.
87. A. Verdecchia, S. Guzzinati et al., Survival trends in European cancer patients diagnosed from 1988 to 1999, European Journal of Cancer 45 (2009), 1042-1066.
88. Vogelbaum, Masarzk et al., S100beta as a Predictor of Brain Metastases: Brain versus Cerebrovascular Damage, Cancer 104 (2005), 817-824.
89. W. Wallace, The challenge of classifying poorly differentiated tumours in the lung, Histopathology 54 (2009), 28-42.
90. B. Wieskopf, C. Demangeat, A. Purohit, Cyfra 21-1 as a Biologic Marker of Non-small Cell Lung Cancer: Evaluation of Sensitivity, Specificity, and Prognostic Role, Chest 108 (1) (1995).
91. W. William, H. Lin, J. Lee et al., Revisiting Stage IIIB and IV Non-small Cell Lung Cancer, Chest (2009), DOI 10.1378/chest.08-2968.
92. M. Wrage, S. Ruosaari, P. Eijik et al., Genomic Profiles Associated with Early Micrometastasis in Lung Cancer: Relevance of 4q Deletion, Clin Cancer Res 15 (5) (2009).
93. E. Wojcik, J. Kulpa, Sas-Korczynska et al., ProGRP and NSE in Therapy Monitoring in Patients with Small Cell Lung Cancer, Anticancer Research 28 (2008), 3027-3034.
94. Wu, Hao et al., Preliminary Investigation of the Clinical Significance of Detecting Circulating Tumor Cells Enriched from Lung Cancer Patients, Journal of Thoracic Oncology 4 (1) (2009), 30-39.
95. G. Wu, E. Wang, J. Li, Z. Fu and S. Han, Clinical application of the liquid-based cytological test in cytological screening of sputum for the diagnosis of lung cancer, Respirology 14 (2009), 124-128.
96. Y. Xie, N. Todd and Z. Liu, Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer, Lung Cancer (2009), doi:10.1016/j.lungcan. 2009.04.004.
97. J. Yee, M. Sadar, D. Sin et al., Connective Tissue-Activating Peptide III: A Novel Blood Biomarker for Early Lung Cancer Detection, J Clin Oncol (2009), 10.1200/JCO.2008.19.4233.